Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
288.45
-5.93 (-2.01%)
At close: Jan 9, 2026, 4:00 PM EST
286.00
-2.45 (-0.85%)
After-hours: Jan 9, 2026, 7:54 PM EST
PRAX Employees
Praxis Precision Medicines had 116 employees as of December 31, 2024. The number of employees increased by 34 or 41.46% compared to the previous year.
Employees
116
Change (1Y)
34
Growth (1Y)
41.46%
Revenue / Employee
$64,336
Profits / Employee
-$2,353,759
Market Cap
7.91B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 116 | 34 | 41.46% |
| Dec 31, 2023 | 82 | -27 | -24.77% |
| Dec 31, 2022 | 109 | -30 | -21.58% |
| Dec 31, 2021 | 139 | 72 | 107.46% |
| Dec 31, 2020 | 67 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRAX News
- 2 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - GlobeNewsWire
- 5 days ago - Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - GlobeNewsWire
- 5 days ago - Praxis Precision Medicines, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 13 days ago - Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
- 13 days ago - Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor - GlobeNewsWire
- 4 weeks ago - Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 - GlobeNewsWire
- 4 weeks ago - Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy - GlobeNewsWire